Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.

Dicko A, Mayer LD, Tardi PG.

Expert Opin Drug Deliv. 2010 Dec;7(12):1329-41. doi: 10.1517/17425247.2010.538678. Review.

PMID:
21118030
2.

Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts.

Lim WS, Tardi PG, Xie X, Fan M, Huang R, Ciofani T, Harasym TO, Mayer LD.

Leuk Lymphoma. 2010 Aug;51(8):1536-42. doi: 10.3109/10428194.2010.490312.

PMID:
20528246
3.

Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.

Lim WS, Tardi PG, Dos Santos N, Xie X, Fan M, Liboiron BD, Huang X, Harasym TO, Bermudes D, Mayer LD.

Leuk Res. 2010 Sep;34(9):1214-23. doi: 10.1016/j.leukres.2010.01.015. Epub 2010 Feb 6.

PMID:
20138667
4.

Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo.

Tardi PG, Dos Santos N, Harasym TO, Johnstone SA, Zisman N, Tsang AW, Bermudes DG, Mayer LD.

Mol Cancer Ther. 2009 Aug;8(8):2266-75. doi: 10.1158/1535-7163.MCT-09-0243. Epub 2009 Aug 11.

5.

Modulating the therapeutic activity of nanoparticle delivered paclitaxel by manipulating the hydrophobicity of prodrug conjugates.

Ansell SM, Johnstone SA, Tardi PG, Lo L, Xie S, Shu Y, Harasym TO, Harasym NL, Williams L, Bermudes D, Liboiron BD, Saad W, Prud'homme RK, Mayer LD.

J Med Chem. 2008 Jun 12;51(11):3288-96. doi: 10.1021/jm800002y. Epub 2008 May 9.

PMID:
18465845
6.

Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes.

Dicko A, Frazier AA, Liboiron BD, Hinderliter A, Ellena JF, Xie X, Cho C, Weber T, Tardi PG, Cabral-Lilly D, Cafiso DS, Mayer LD.

Pharm Res. 2008 Jul;25(7):1702-13. doi: 10.1007/s11095-008-9561-z. Epub 2008 Mar 5.

PMID:
18320294
7.
8.

Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.

Tardi PG, Gallagher RC, Johnstone S, Harasym N, Webb M, Bally MB, Mayer LD.

Biochim Biophys Acta. 2007 Mar;1768(3):678-87. Epub 2006 Dec 6.

9.

Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice.

Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB, Janoff AS.

Mol Cancer Ther. 2006 Jul;5(7):1854-63.

10.

Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity.

Dos Santos N, Waterhouse D, Masin D, Tardi PG, Karlsson G, Edwards K, Bally MB.

J Control Release. 2005 Jun 20;105(1-2):89-105.

PMID:
15878792
11.

Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes.

Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox KA, Tardi PG, Bally MB.

Biochim Biophys Acta. 2002 Apr 12;1561(2):188-201.

12.

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.

Waterhouse DN, Tardi PG, Mayer LD, Bally MB.

Drug Saf. 2001;24(12):903-20. Review.

PMID:
11735647
13.

Antibody conjugation methods for active targeting of liposomes.

Ansell SM, Harasym TO, Tardi PG, Buchkowsky SS, Bally MB, Cullis PR.

Methods Mol Med. 2000;25:51-68. doi: 10.1385/1-59259-075-6:51.

PMID:
21318840
14.

An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin.

Tardi PG, Swartz EN, Harasym TO, Cullis PR, Bally MB.

J Immunol Methods. 1997 Dec 29;210(2):137-48.

PMID:
9520297
15.

3-(2-pyridyldithio)propionic acid hydrazide as a cross-linker in the formation of liposome-antibody conjugates.

Ansell SM, Tardi PG, Buchkowsky SS.

Bioconjug Chem. 1996 Jul-Aug;7(4):490-6.

PMID:
8853463
16.

Liposomal doxorubicin.

Tardi PG, Boman NL, Cullis PR.

J Drug Target. 1996;4(3):129-40. Review.

PMID:
8959485
17.

Accumulation of protein-coated liposomes in an extravascular site: influence of increasing carrier circulation lifetimes.

Longman SA, Tardi PG, Parr MJ, Choi L, Cullis PR, Bally MB.

J Pharmacol Exp Ther. 1995 Dec;275(3):1177-84.

PMID:
8531079
18.

The modulation of phosphatidylinositol biosynthesis in hamster hearts by methyl lidocaine.

Lee E, Tardi PG, Man RY, Choy PC.

Biochem J. 1995 Aug 1;309 ( Pt 3):871-6.

19.

Effects of selenium supplement on the de novo biosynthesis of glycerolipids in the isolated rat heart.

Liu SY, Tardi PG, Choy PC, Man RY.

Biochim Biophys Acta. 1993 Nov 3;1170(3):307-13.

PMID:
8218350
20.

Modulation of phosphatidylethanolamine biosynthesis by exogenous ethanolamine and analogues in the hamster heart.

McMaster CR, Tardi PG, Choy PC.

Mol Cell Biochem. 1992 Oct 21;116(1-2):69-73.

PMID:
1480155
21.
22.

Solubilization and modulation of acyl-CoA:1-acyl-glycerophosphocholine acyltransferase activity in rat liver microsomes.

Mukherjee JJ, Tardi PG, Choy PC.

Biochim Biophys Acta. 1992 Jan 3;1123(1):27-32.

PMID:
1730043
23.

The quantitation of long-chain acyl-CoA in mammalian tissue.

Tardi PG, Mukherjee JJ, Choy PC.

Lipids. 1992 Jan;27(1):65-7.

PMID:
1608307
24.

Lysophosphatidylcholine acyltransferase.

Choy PC, Tardi PG, Mukherjee JJ.

Methods Enzymol. 1992;209:80-6. No abstract available.

PMID:
1495439
25.

The effect of methyl lidocaine on lysophospholipid metabolism in hamster heart.

Tardi PG, Man RY, McMaster CR, Choy PC.

Biochem Cell Biol. 1990 Apr;68(4):745-50.

PMID:
2222999

Supplemental Content

Loading ...
Support Center